Fortrea Holdings (FTRE) Share-based Compensation (2022 - 2026)
Fortrea Holdings (FTRE) posted Share-based Compensation of $11.4 million for Q1 2026, down 84.68% on a QoQ basis from $74.4 million in Q4 2025, and down 21.92% year-over-year from $14.6 million in Q1 2025.
Fortrea Holdings (FTRE) Share-based Compensation (2022 - 2026) Analysis & Trends
Fortrea Holdings' Share-based Compensation history runs 5 years deep, the most recent figure standing at $11.4 million for Q1 2026.
- Quarterly Share-based Compensation fell 21.92% year-over-year to $11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $71.2 million (up 22.97% YoY) and the FY2025 annual result came in at $74.4 million, up 27.4% from the prior year.
- Share-based Compensation was $11.4 million for Q1 2026 at Fortrea Holdings, down from $74.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $74.4 million in Q4 2025 and bottomed at -$37.3 million in Q3 2025.
- A 5-year average of $13.3 million and a median of $13.0 million in 2024 frame the typical range for Share-based Compensation.
- Peak annual rise in Share-based Compensation reached 386.27% in 2025, while the deepest fall reached 386.92% in 2025.
- Fortrea Holdings' Share-based Compensation stood at $5.8 million in 2022, then soared by 167.24% to $15.5 million in 2023, then retreated by 1.29% to $15.3 million in 2024, then soared by 386.27% to $74.4 million in 2025, then slumped by 84.68% to $11.4 million in 2026.
- Business Quant data shows FTRE's Share-based Compensation at $11.4 million in Q1 2026, $74.4 million in Q4 2025, and -$37.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | 11.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.40 Mn |
| Mar 31, 2026 | 11.40 Mn |
| Dec 31, 2025 | 74.40 Mn |
| Dec 31, 2025 | 74.40 Mn |
| Sep 30, 2025 | -37.30 Mn |
| Sep 30, 2025 | -37.30 Mn |
| Jun 30, 2025 | 22.70 Mn |
| Jun 30, 2025 | 22.70 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Mar 31, 2025 | 14.60 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Dec 31, 2024 | 15.30 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 15.00 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Mar 31, 2024 | 15.10 Mn |
| Dec 31, 2023 | 15.50 Mn |
| Dec 31, 2023 | 15.50 Mn |